



2024 PRIOR AUTHORIZATION REQUEST FORM
Individual and Family Plans

Kerendia

Fax back to: (833) 605-4407

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
Member Number:	Fax: Phone:
Date of Birth:	Office Contact:
Line of Business: <input type="checkbox"/> Exchange - PA	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	Specialty/facility name (if applicable):

REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Does the member have chronic kidney disease associated with type 2 diabetes (CKD with T2D)? Please attach documentation.

Yes

No

Q2. Is Kerendia being prescribed by or in consultation with nephrologist, cardiologist, or endocrinologist?

Yes

No

Q3. Have all potential contraindications (concomitant treatment with strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin), adrenal insufficiency, GFR less than 25 mL/min) been excluded?

Yes

No

Q4. Will the member continue therapy with an ACE or ARB at maximally tolerated doses for diabetic nephropathy, or is there an intolerance or contraindication to these therapies?

Yes

No



2024 PRIOR AUTHORIZATION REQUEST FORM
Individual and Family Plans

Kerendia

Fax back to: (833) 605-4407

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
----------------------	-------------------------

Q5. Has the patient had a documented inadequate response, intolerance or contraindication to one sodium-glucose co-transporter 2 (SGLT2) inhibitor used for chronic kidney disease (e.g., Farxiga)?

Yes

No

Q6. Additional Information:

Prescriber Signature

Date

2024 Prior Authorization Request